期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
CPET评估制定运动处方强度指导对CHF患者血压、CPET指标以及生命质量的影响 被引量:1
1
作者 吴秀娟 王忠民 +2 位作者 刘伟利 林松 周湘鸿 《临床医学》 CAS 2019年第1期5-9,共5页
目的分析心肺运动功能测试(CPET)评估制定运动处方强度指导对慢性心力衰竭患者血压、CPET指标以及生命质量的影响。方法选取2018年1月至2018年3月慢性心力衰竭(CHF)患者50例,入院后均给予常规治疗及护理,并进行CPET评估,根据评估结果制... 目的分析心肺运动功能测试(CPET)评估制定运动处方强度指导对慢性心力衰竭患者血压、CPET指标以及生命质量的影响。方法选取2018年1月至2018年3月慢性心力衰竭(CHF)患者50例,入院后均给予常规治疗及护理,并进行CPET评估,根据评估结果制定踏车运动康复处方,根据运动负荷强度分为对照组(n=25)和研究组(n=25),分别以80%无氧阈水平和无氧阈以上50%功率强度进行12周心脏运动康复干预。比较两组患者的血压、心率、CPET指标以及生命质量、超声心动图指标。结果干预前后,两组患者心率、舒张压以及收缩压比较,差异未见统计学意义(P>0.05);干预后12周,研究组明尼苏达心力衰竭生活质量调查表(MLHFQ)评分显著低于对照组,6 min步行试验(6MWD)显著高于对照组,差异有统计学意义(P<0.05);研究组峰值氧脉搏、峰值摄氧量以及无氧阈均显著高于对照组,差异有统计学意义(P<0.05);两组患者均未出现不良事件。结论在CPET评估制定运动处方强度指导下,高强度的心脏康复运动可以显著提高CHF患者的生命质量、心肺功能以及运动耐力,且不增加不良事件的发生,值得临床重视。 展开更多
关键词 慢性心力衰竭 心脏康复运动 心肺运动功能测试
原文传递
Enhancing DNA vaccine potency against hantavirus by co-administration of interleukin-12 expression vector as a genetic adjuvant 被引量:4
2
作者 ZHENGLan-yan MOULing +2 位作者 linsong LURun-ming LUOEn-jie 《Chinese Medical Journal》 SCIE CAS CSCD 2005年第4期313-319,共7页
Background The heavy incidence and mortality of hemorrhagic fever with renal syndrome, as well as no specific drugs in curing the disease, clearly indicate the need for development Of the more effective hantavirus vac... Background The heavy incidence and mortality of hemorrhagic fever with renal syndrome, as well as no specific drugs in curing the disease, clearly indicate the need for development Of the more effective hantavirus vaccine. Refining the DNA vaccination strategy to elicit more clinically efficacious immune responses is now under intensive investigation. In the present study, we examined the effects of using an interleukin-12 expression plasmid as a genetic adjuvant to enhance the immune responses induced by a DNA vaccine based on the S gene encoding nucleocapsid protein against hantavirus. Methods BALB/c mice were immunized three times by intramuscular inoculations of DNA vaccine encoding of hantanvirus nucleoeapsid protein alone or in combination with a plasmid expressing murine interleukin-12 (pcIL-12). Booster immunizations were employed 2 times at 2-week interval. To evaluate the Immoral and cellular immune responses, antigen-specific lymphocyte proliferation and antibody production were assayed by MTT method and ELISA respectively. The level of interleukin-4 and interferon-gamma in the splenic lymphocytic cultured supernatant were detected with ELISA kit at day 5, 10, 17, 35 and 42 after primary immunization. Results Antigen-specific IgG antibodies was increased markedly at day 17 in the experiment groups and reached a plateau after day 35. As pcIL-12 co-injected, a significant inhibition of antigen-specific IgG levels was displayed over the period and the antibody mean titre was decreased to only about 1: 50 at day 42 after primary immunization, significantly lower than the group immunized with pcDNA3.1 + S alone, in which the mean titre was about 1:70. Interferon-gamma was increased remarkably by the co-injection of pcIL-12 compared with the injection of pcDNA3.1 + S alone. However, the production of interleukin-4 was inhibited by pcIL-12 coinjection. Furthermore, pcIL-12 co-injection efficiently enhanced antigen-specific lymphocyte proliferation. Conclusion Humoral and cytokine responses elicited by pcDNA3.1 + S inoculation can be modulated by coinoculation with pcIL-12 and efficiently induced Th1-dominant immune responses. 展开更多
关键词 DNA vaccines HANTAVIRUS gene adjuvant INTERLEUKIN-12 nucleocapsid proteins
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部